Prevention of atheroslerotic cardiovascular events in frail patiens
Authors:
J. Piťha
Published in:
Geriatrie a Gerontologie 2017, 6, č. 4: 158-162
Category:
Review Article
Overview
Cardiovascular events of atherosclerotic origin most often affect older people. In elderly patients however, in addition to advanced and complex changes in the cardiovascular system, we are facing further long-term illnesses and additionally the consequences of their treatment. Older patients also experience different responses to treatment due to different pharmacodynamics and pharmacokinetics; these patients also take other drugs that could adversely interact with our treatment. The situation is further complicated by the generally worse cooperation because of impaired cognitive abilities in seniors. On the one hand, elderly patients with high cardiovascular risk benefit from the appropriate treatment most; on the other hand, they are often more sensitive to adverse effects of some drugs. However, appropriate treatment and prevention of cardiovascular diseases can also improve substantially overall condition of the patient and thus reduce his or her frailty. Among the most successful drugs in this respect are hypolipemic drugs, statins, and some antihypertensive drugs. Even in advanced age, the course of many illnesses could be also significantly affected by appropriate lifestyle measures. We have tried to discuss this topic in more detail in this article.
Keywords:
cardiovascular disease – atherosclerosis – elderly – management – frailty
Sources
1. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 2015; 116(2): 307–311.
2. Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M156.
3. Strandberg TE, Pitkälä KH. Frailty in elderly people. Lancet 2007; 369: 1328–1329.
4. Shamliyan T, Talley KM, Ramakrishnan R, et al. Association of frailty with survival: a systematic literature review. Ageing Res Rev 2013; 12: 719–736.
5. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call toaction. J Am Med Dir Assoc 2013; 14: 392–397.
6. de Vries NM, Staal JB, van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev 2011; 10: 104–114.
7. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381: 752–762.
8. Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovasc Disord 2016; 16(1): 208.
9. Benetos A, Bulpitt CJ, Petrovic M, et al. An expert opinion from the European society of hypertension-European union geriatric medicine society working group on the management of hypertension in very old, frail subjects. Hypertension 2016; 67(5): 820–825.
10. Pitha J, Lesná K, Sekerkova A, et al. Menopausal transition enhances the atherogenic risk of smoking in middle aged women. Int J Cardiol 2013; 168(1): 190–196.
11. Pedro-Botet J, Climent E, Chillarón JJ, et al. Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol 2015; 12(4): 431–438.
12. Greco A, Paroni G, Seripa D, et al. Frailty, disability and physical exercise in the aging process and in chronic kidney disease. Kidney Blood Press Res 2014; 39(2–3): 164–168.
13. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282(24): 2340–2346.
14. Pella D, Gvozdjáková A, Lietava A, et al. Myopatie asociovaná se statiny: klinické doporučení Slovenskej asociácie aterosklerózy a České společnosti pro aterosklerózu. Atherorevue 2016; 1(1): 7–13.
15. Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688–697.
16. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013; 88: 1213–1221.
17. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group.: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–1898.
18. Kubesova HM, Weber P, Meluzinova H, et al. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013; 125(15–16): 425–436.
19. Creus-Cuadros A, Tresserra-Rimbau A, Quifer-Rada P, et al.; PREDIMED Study Investigators: Associations between Both Lignan and Yogurt Consumption and Cardiovascular Risk Parameters in an Elderly Population: Observations from a Cross-Sectional Approach in the PREDIMED Study. J Acad Nutr Diet 2017; 117(4): 609–622
20. Tresserra-Rimbau A, Guasch-Ferré M, Salas-Salvadó J, et al.; PREDIMED study investigators. Intake of Total Polyphenols and Some Classes of Polyphenols Is Inversely Associated with Diabetes in Elderly People at High Cardiovascular Disease Risk. J Nutr 2016; Mar 9.
21. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: 1909.
22. Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the elderly. J Clin Oncol 2014; 32(24): 2654–2661.
23. Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New An Evolving Avenue. Circulation 2016; 133(13): 1272–1289.
24. Damluji AA, Ramireddy A, Otalvaro L, et al. Secondary cardiovascular prevention in older adults: an evidence based review. J Geriatr Cardiol 2015; 12(5): 459–464.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2017 Issue 4
Most read in this issue
- Gastrointestinal bleeding – a significant risk for geriatric patients
- Securing vascular access in geriatric patients
- COPD – news in diagnostics and treatment
- A frail patient with kidney failure